CLOS
ACHN

Compagnie Lombard Odier SCmA’s Achillion Pharmaceuticals ACHN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,000
Closed -$34K – 680
2017
Q4 		$34K Buy
12,000
+6,000
+100% +$21.8K ﹤0.01% 561
2017
Q3 		$27K Hold
6,000
– – ﹤0.01% 585
2017
Q2 		$28K Sell
6,000
-32,200
-84% -$129K ﹤0.01% 588
2017
Q1 		$161K Sell
38,200
-30,000
-44% -$125K 0.01% 388
2016
Q4 		$282K Sell
68,200
-4,000
-6% -$21.3K 0.01% 399
2016
Q3 		$584K Hold
72,200
– – 0.02% 334
2016
Q2 		$563K Sell
72,200
-8,000
-10% -$68.6K 0.02% 326
2016
Q1 		$620K Hold
80,200
– – 0.02% 316
2015
Q4 		$866K Buy
80,200
+7,000
+10% +$63.6K 0.03% 255
2015
Q3 		$506K Sell
73,200
-10,000
-12% -$81.5K 0.02% 273
2015
Q2 		$737K Buy
83,200
+77,200
+1,287% +$730K 0.03% 254
2015
Q1 		$59K Hold
6,000
– – ﹤0.01% 766
2014
Q4 		$73K Hold
6,000
– – ﹤0.01% 596
2014
Q3 		$60K Buy
+6,000
New +$55.7K ﹤0.01% 706

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ACHN Position: Q1 2018 in Review

Compagnie Lombard Odier SCmA sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 12,000 shares — an estimated $34K sold.

Compagnie Lombard Odier SCmA first reported a position in ACHN in Q3 2014 and held it in 14 quarters. The position peaked at $866K in Q4 2015. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Compagnie Lombard Odier SCmA reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 12,000 Achillion Pharmaceuticals shares in Q1 2018, an estimated $34K.
  • Compagnie Lombard Odier SCmA first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 14 quarters.
  • Compagnie Lombard Odier SCmA's Achillion Pharmaceuticals position peaked at $866K in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2018, filed 11 May 2018.